Background Personalized medicine and orphan drugs share many characteristics—both
target small patient populations, have uncertainties regarding efficacy and safety at payer
submission, and frequently have high prices. Given personalized medicine's rising
importance, this review summarizes international coverage and pricing strategies for
personalized medicine and orphan drugs as well as their impact on therapy development
incentives, payer budgets, and therapy access and utilization. Methods PubMed, Health …